ABT 263;
AEG 35156;
ANTISENSE OLIGONUCLEOTIDE;
BCL2 RELATED PROTEIN A1;
BEVACIZUMAB;
CASPASE;
DEATH RECEPTOR;
DOCETAXEL;
GOSSYPOL DERIVATIVE;
HGS 1029;
IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;
INHIBITOR OF APOPTOSIS PROTEIN;
ISOSORBIDE;
LEXATUMUMAB;
LY 2181308;
MAPATUMUMAB;
OBATOCLAX;
OBLIMERSEN;
PROTEIN BCL 2;
PROTEIN BCL W;
PROTEIN BCL XL;
PROTEIN MCL 1;
PROTEIN MDM2;
PROTEIN P53;
RITUXIMAB;
SPC 2996;
SURVIVIN;
TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
X LINKED INHIBITOR OF APOPTOSIS;
YM 155;
ADJUVANT THERAPY;
APOPTOSIS;
ARTICLE;
CANCER STAGING;
CANCER SURVIVAL;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG TARGETING;
FOOD AND DRUG ADMINISTRATION;
HEMATOLOGIC MALIGNANCY;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG SMALL CELL CANCER;
MALIGNANT NEOPLASTIC DISEASE;
MELANOMA;
MEMBRANE DAMAGE;
MITOCHONDRIAL MEMBRANE;
PRIORITY JOURNAL;
PROSTATE CANCER;
PROTEIN DEGRADATION;
PROTEIN FAMILY;
ANTINEOPLASTIC AGENTS;
APOPTOSIS;
DRUG DESIGN;
HUMANS;
NEOPLASMS;
PROTO-ONCOGENE PROTEINS C-BCL-2;
RECEPTORS, CELL SURFACE;
RECEPTORS, DEATH DOMAIN;
Randomised Phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia
O'Brien, S. et al. Randomised Phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. Cancer Res. 68, 3421-3428 (2008).
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
Paoluzzi, L. et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 111, 5350-5358 (2008).
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)
Konopleva, M. et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 68, 3413-3420 (2008).
Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: A breakthrough in anticancer therapy
Labi, V. et al. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: A breakthrough in anticancer therapy. Cell Death Differ. 15, 977-987 (2008).
A phase Ib safety and pharmacokinetic study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma
Yee, L. et al. A phase Ib safety and pharmacokinetic study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma. J. Clin. Oncol. 25 (Suppl. 18), 8078 (2007).
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
Greco, F. A. et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61, 82-90 (2008).
